Infusible Medication Pipeline

This topic has 1 reply, 2 voices, and was last updated 1 year, 8 months ago by Avatar Donnalussier.

  • Author
  • #14081

    Are you tired of being caught off-guard by patients asking for a new medication on the market that you’ve never heard of? Well, we’ve got some good news…

    NICA publishes quarterly pipeline reports! We have two late-stage pipeline reports, one for IV/injectable medications and one for IV/inj. biosimilars. Both reports capture “late-stage” products, including those: in Phase III clinical trials, that have been filed for approval, that have been approved, and that have come to market. The late-stage IV/inj. report captures both primary and secondary indications. We also release a change summary with each report to capture the changes since the previous quarter’s report.

    How could it get any better, you ask? Well, NICA paid-members get a discount!

    So, subscribe to the pipeline reports, sit back, and stay up-to-speed on new therapeutic options you could be administering in your infusion suite!

    Lead Goon, Team NICA


    This sounds like a wonderful resource!! When you state “come to the market”, are you speaking globally or just the U.S.?

Viewing 2 posts - 1 through 2 (of 2 total)

You must be logged in to reply to this topic.


Thank you for your interest in NICA. We are eager to connect with you and to discuss the exciting work of increasing patient access to infusible and injectable therapies.

If you have questions or concerns, please send us an email and a member of our team will contact you shortly.


Log in with your credentials


Forgot your details?

Create Account